How to evaluate risk and identify stage II patients requiring referral to a medical oncologist: a surgeon's perspective.
The surgical oncologist's ability to identify which patients with stage II colon cancer should be referred to a medical oncologist is subjective and qualitative. It includes assessment of the qualitative aspects of the pathology reports, the patient's suitability to receive potentially toxic medication, and their personal preference. The prognosis of colorectal cancer varies greatly in accordance with disease stage and tumor site. Patients with stage II colon cancer are cured with surgery alone in 75% to 80% of cases. This means that if all patients with stage II tumors are referred to a medical oncologist, a large number will receive treatment that is not necessary and potentially toxic. If none are referred, some will be undertreated. The question is how to identify those who should appropriately be considered for adjuvant therapy. In this article, we will discuss the strengths and limitations of the factors that must be considered when making the decision to refer to a medical oncologist or not.
Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ian C
IC
Lavery
Luiz Felipe
LF
De Campos-Lobato
D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D012017:Referral and Consultation; D018570:Risk Assessment